Liraglutide
Product-specific diabetes information. Do not merge every liraglutide brand or indication.
FDA-approved product context
Product-specific diabetes information. Do not merge every liraglutide brand or indication.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
The retrieved November 2025 liraglutide injection label describes a subcutaneous GLP-1 receptor agonist and type 2 diabetes evidence. Different branded products and indications must be read separately.
The boxed warning concerns thyroid C-cell tumors. The label also describes pancreatitis, hypoglycemia, kidney injury from volume depletion, gastrointestinal effects, hypersensitivity and gallbladder disease.
Approval applies to the specific labeled product, route and indication, not every preparation of this ingredient or a wellness mixture. Read the original full label and discuss individual circumstances with a medical professional. No dosing or preparation instructions are included.
Original source: Liraglutide ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.